SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Supplements/Peptide

Tesamorelin (Ref)

GHRH analog approved for HIV-associated visceral adiposity.

Growth Hormone Support

Overview

GHRH analog approved for HIV-associated visceral adiposity.

Natural sources
    Common forms

      Mechanism of action

      Stimulates endogenous GH release via pituitary GHRH receptor.

      Pathways

        Effects on the body

        Organ system effects

        Evidence-based benefits

        Reduces visceral adipose tissue

        Strong evidence

        Potential side effects

        Common
        • · Injection site reactions
        Rare
          Serious
          • · Hyperglycemia

          Drug interactions

          No notable interactions reported.

          Safety & non-supplemental interactions

          Educational summary — always confirm with your clinician or pharmacist before starting, stopping, or combining with prescription therapy.

          Avoid if you are
          • ·Pregnant or breastfeeding (insufficient safety data)
          • ·Children under 18 (unless directed by a clinician)
          Other notes
          • ·Most research peptides are not FDA-approved for human use outside investigational protocols.

          Supplement interactions

          Pairs well with

          None listed.

          Avoid combining with

          No specific avoidances listed.

          Dosing & bioavailability

          Typical dose
          2 mg SC daily (Rx)

          Where to buy

          Affiliate-style search links to reputable retailers. We don't endorse specific brands — verify third-party testing (USP, NSF, Informed Sport) before purchase.

          Peptide
          Tesamorelin …
          Amazon
          Wide selection · fast shipping
          Peptide
          Tesamorelin …
          iHerb
          Global delivery · curated brands
          Peptide
          Tesamorelin …
          Thorne
          Practitioner-grade · NSF tested

          Scientific evidence (8)

          RCTN Engl J Med · 2007

          Tesamorelin in HIV lipodystrophy

          Falutz J, et al.

          26-week DB-RCT in 412 HIV patients.

          Key findings

          Reduced VAT by ~15% vs placebo.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — Reduces visceral adipose tissue

          Live PubMed search

          Live results for "Tesamorelin (Ref) Reduces visceral adipose tissue" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "Reduces visceral adipose tissue". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — randomized controlled trial

          Live PubMed search

          Live results for "Tesamorelin (Ref) randomized controlled trial" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "randomized controlled trial". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — meta-analysis

          Live PubMed search

          Live results for "Tesamorelin (Ref) meta-analysis" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "meta-analysis". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — pharmacokinetics

          Live PubMed search

          Live results for "Tesamorelin (Ref) pharmacokinetics" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "pharmacokinetics". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — safety adverse events

          Live PubMed search

          Live results for "Tesamorelin (Ref) safety adverse events" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "safety adverse events". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewPubMed (NLM) · 1970

          PubMed: Tesamorelin (Ref) — dose response

          Live PubMed search

          Live results for "Tesamorelin (Ref) dose response" across the PubMed/MEDLINE peer-reviewed index.

          Key findings

          Opens current human and preclinical literature matching Tesamorelin (Ref) and "dose response". Filter by RCT, meta-analysis, or year on the results page.

          Open study
          Systematic reviewGoogle Scholar · 1970

          Google Scholar: Tesamorelin (Ref) — clinical evidence

          Live Scholar search

          Cross-database citation index for Tesamorelin (Ref) as it relates to "clinical evidence".

          Key findings

          Includes preprints, theses, and journal articles. Useful for tracking citation counts and follow-on work.

          Open study
          Educational use only. This profile is not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take prescription medication or have a chronic condition.